Endothelial Dysfunction in Non-Alcoholic Fatty Liver Disease

2018 ◽  
Author(s):  
C Anjana ◽  
S Sharmila ◽  
V Balasubramaniyan
Keyword(s):  
Liver Disease ◽  
Endothelial Dysfunction ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-alcoholic fatty liver disease may be associated with endothelial dysfunction

2013 ◽  
Vol 119 (1) ◽  
pp. 57-57 ◽  
Author(s):  
Sevket Balta ◽  
Sait Demirkol ◽  
Zekeriya Arslan ◽  
Mustafa Demir ◽  
Murat Unlu ◽  
...  
Keyword(s):  
Liver Disease ◽  
Endothelial Dysfunction ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals PECULIARITIES OF SYSTEMIС INFLAMMATION OF LOW INTENSITY IN PATIENTS WITH STABLE CORONARY HEART DISEASE CONCURRENT WITH NON-ALCOHOLIC FATTY LIVER DISEASE

2019 ◽  
Vol 23 (3-4) ◽  
pp. 3-6 ◽  
Author(s):  
Yu.I. Manusha ◽  
Yu.M. Kazakov ◽  
Т.А. Trybrat ◽  
K.E. Ischeykin
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Liver Disease ◽  
Endothelial Dysfunction ◽  
Fatty Liver ◽  
Systemic Inflammation ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Low Intensity ◽  
Alcoholic Fatty Liver Disease

Nowadays, coronary heart disease and non-alchoholic fatty liver disease are significant problems in Ukraine and world. Functional liver disorders potentiate the development and progression of CHD. The initiation process of atherosclerosis is a chronic systemic inflammation of low intensity. This view on atherosclerosis development has been forming during the past two decades. The aim of the research was to study the features/characteristics of systemic inflammation of low intensity in patients with coronary heart disease in combination with non-alcoholic fatty liver disease. The research involved 135 people with CHD: stable angina, I-II functional class, 0-I heart failure in combination with non-alcoholic fatty liver disease and 30 healthy individuals. We examined patients in terms of blood levels of cytokines -TNFα and IL-10, the content of the acute phase reactant and the coagulation factor, the marker of endothelial dysfunction is the amount of circulating endothelial microparticles (CEM) CD32+ CD40+ and the expression level of IkBα gene NF-kB in mononuclear peripheral blood. We studied the level of expression of the mRNA gene of IkBα in mononuclear cells, which reflects the level of transcriptional activity of NF-kB in patients with stable coronary artery disease and CHD in combination with NAFLD showed a significant increase in the expression of the mRNA gene of IkBα by 88.5% compared to patients with stable stable coronary heart disease. The analysis of the functional state of the endothelium with help of CEM CD32+ CD40+ has shown the presence of endothelial dysfunction in the groups of patients with CHD and CHD in combination with of NAFLD. Comparison of the indicators of systemic inflammation of low intensity and marker of endothelial dysfunction in patients with CHD in combination with NAFLD revealed a significant increase of TNFα, acute phase reactant and coagulation fibrinogen factor and expression of the mRNA IkBα gene in patients with comorbidity, indicating an increase the level of systemic inflammation of low intensity in patients with CHD in combination with NAFLD as compared with the group of patients with CHD.

Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study

2017 ◽  
Vol 26 (3) ◽  
pp. 261-268 ◽  
Author(s):  
Marcello Dallio ◽  
Mario Masarone ◽  
Giuseppe Gerardo Caprio ◽  
Rosa Di Sarno ◽  
Concetta Tuccillo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liver Disease ◽  
Endothelial Dysfunction ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is emerging as an independent cardiovascular risk factor. Recently, Endocan has been studied as an early marker of endothelial dysfunction. Our aim was to evaluate Endocan serum levels in patients with NAFLD with or without type 2 diabetes mellitus.Method: We enrolled 56 patients: 19 with NAFLD and 37 with type 2 diabetes mellitus with or without NAFLD, and compared them to 25 healthy controls. Endocan serum level was measured by using the ELISA EndoMark assay.Results: Endocan level was significantly higher in NAFLD subjects, compared to controls (1.23±1.51 vs 0.68±0.4 ng/mL; p=0.016). It was higher in patients with non-alcoholic fatty liver and non-alcoholic steatohepatitis (NASH) (1.12±1.11, 1.49±2.16 and 0.68±0.4 ng/ml vs controls, respectively), independently from presence of type 2 diabetes mellitus. The increase was more marked in patients with NASH and in those with NAFL versus controls (p=0.001 and p=0.004, respectively), but not statistically different between the two groups (p=0.448). Finally, we found a statistically relevant increase of this marker in diabetic NAFLD patients compared to those non diabetic (1.56±0.81 vs 0.72±0.58 ng/ml; p=0.01).Conclusion: We demonstrated an increased Endocan serum level in NAFLD patients, higher in those with type 2 diabetes mellitus and/or NASH because of an endothelial dysfunction in these pathologies.Abbreviations: BMI: Body Mass Index; CCBS: calcium channel blockers; ED: endothelial dysfunction; ELISA: enzyme-linked immunosorbent assay; ESM-1: Endothelial cell-specific molecule-1; HOMA-IR: Homeostasis Model Assessment Insulin Resistance; ICAM: Intercellular Adhesion Molecule; LFA-1: Lymphocyte Function-Associated Antigen 1; NAFL: non-alcoholic fatty liver; NAFLD: Non-alcoholic fatty liver disease; NAS: non-alcoholic fatty liver disease activity score; NASH: non-alcoholic steatohepatitis; ROS: reactive oxigen species; T2DM: type 2 diabetes mellitus; TNF-alpha: tumor necrosis factor-alpha.

scholarly journals Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease

PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0156650 ◽  
Author(s):  
Francisco Javier Gonzalez-Paredes ◽  
Goretti Hernández Mesa ◽  
Dalia Morales Arraez ◽  
Raquel Marcelino Reyes ◽  
Beatriz Abrante ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Liver Disease ◽  
Endothelial Dysfunction ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
End Products ◽  
And Oxidative Stress ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document